

PREVENTION & THERAPIES FOR HEPATITIS AND CHRONIC LIVER DISEASE

Phoenix, AZ – September 17-18, 2021

**Conference
Location**

Desert Willow Conference Center
4340 East Cotton Center Blvd.
Phoenix, AZ 85040

Phone: (602) 431-0001

<http://www.desertwillowconferencecenter.com>

**Parking at the
Conference**

Parking is complimentary for all participants.

**Driving
Directions**

From the North: Take I-17 South towards Tucson. Merge onto I-10 East via the exit on the left towards Globe/Tucson. **Exit at 40th Street.** Turn right onto South 40th Street and left onto East Cotton Center Boulevard. Desert Willow will be on your left.

From East Valley: Take US-60 West, merge onto I-10 West and exit at Broadway Road. Turn left onto Broadway Road and left onto South 48th Street. Turn right onto East Cotton Center Boulevard, pass through 1 roundabout and Desert Willow will be on your right.

From the West: Take I-10 East to 40th Street. Turn right onto 40th Street and turn left onto east Cotton Center Boulevard. Desert Willow will be on your left.

**Seminar Agenda
and Syllabus
Information**

Registration and breakfast begin at **7:30 a.m.** in the **Brittlebrush Ballroom** Please check signage for any last-minute room changes.

This seminar is a paperless program. **The course syllabus and related materials will be made available on a digital app** that can be accessed by a smart phone, tablet device or personal computer. Instructions to download the *App* will be provided to participants in advance of the seminar. Wi-Fi will be available without charge.

Day 1 12:00 -1:00pm	Registration and View Exhibits
1:00 pm	Opening Comments and Pre-Test
1:15 pm	Viral Hepatitis, Discovery of HCV and Its Natural History
2:00 pm	Hepatitis C: Update on Diagnostics Hepatitis C: Update on Treatment
3:00 pm	Break and View exhibits
3:15 pm	Hepatitis B: Epidemiology, Natural History and Testing
3:45 pm	Anti-viral Therapies for HBV
4:40pm	Delta Hepatitis and Hepatitis E Update from AASLD and EASL Case Studies 1 and 2 –HIV/HCV Co-infection; Infections in persons who inject drugs.
5:10 pm	Product Presentation, Exhibitor Showcase and Reception
6:30 pm	Day 1 concludes
Day 2 7:30 am	Breakfast and View Exhibits
8:00 am	End Stage Liver Disease: Treatment, Managing Complications and Transplant

	Liver Transplantation Case Study 3 – Cirrhosis and Encephalopathy
8:55 am	Hepatocellular Carcinoma (HCC)
9:25 am	Hepatocellular Carcinoma: New Systemic Treatment Options Case Study 4– Diagnosis and Treatment of Hepatocellular Carcinoma
10:15 am	Break & View Exhibits
10:30 am	Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis
11:15 am	Viral Hepatitis Updates <ul style="list-style-type: none"> • The reemergence of Hepatitis A and Alcoholic liver disease
11:45 am	SARS-COV-2 in Liver Disease
12:15 pm	Luncheon Presentation
1:15 pm	NAFLD, LAL-D and NASH
2:10 pm	Break & View Exhibits
2:25 pm	NASH Treatments in Practice and in Development
3:30 pm	Closing Comments, Post-test and Wrap-Up Program adjourns at 3:45pm

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Attendance Policies

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.


CME Information

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **10.0 AMA PRA Category 1 Credit(s)TM**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 12.0 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-22-1205. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)TM organizations accredited by ACCME.

**Your
Seminar
Faculty**



RICHARD A. MANCH, MD, FAASLD, FACG

Dr Richard A. Manch currently serves as Chief of Hepatology at Arizona Liver Health, with research and clinic sites in Chandler, Glendale and Tucson, Arizona. He is board certified in Internal Medicine, Gastroenterology and Transplant Hepatology. A graduate of the State University of New York in Buffalo (B.A., M.D.), he also holds a master's degree in Health Administration from the University of Colorado. He is a Fellow of the American College of Physicians, the American College of Gastroenterology and the American College of Physician Executives and is Clinical Professor of Medicine with the University of Arizona and Professor of Medicine with Creighton University.

Dr. Manch has been instrumental in developing two liver transplant programs in Arizona and developed an extensive network of liver disease outreach clinics throughout the state, before redirecting his efforts toward the development of innovative ways to provide specialized Hepatology consultation by teleconferencing with primary providers in medically underserved areas.



HUGO E. VARGAS, MD, MS, FACP, FAASLD

Hugo Vargas received his medical degree from Hahnemann University Graduate School of Medicine in Philadelphia, PA after graduating with a BS in Physiology from UC Davis. Concurrently, he expanded his study in Human Physiology receiving a Master's of Science degree.

Dr. Vargas is certified in Internal Medicine, Gastroenterology and Transplant Hepatology. Clinically, Dr. Vargas is interested in hepatitis, End-stage liver disease and hepatocellular carcinoma. He participates in clinical and diagnostic trials and collaborates with research partners at the Mayo Clinic and with national experts in the treatment of liver disease.

He is the recipient of many professional and academic awards including Outstanding Fellowship Director of the Year and Investigator of the Year at Mayo. Dr. Vargas is also active in AASLD and serves on their education, research and membership committees. IN 2014, he was awarded Fellowship in AASLD



ANN MOORE, FNP-C

Ann Moore has over 30 years of liver disease and complex liver transplant management experience. As a board-certified nurse practitioner, Ann is recognized nationally for her liver disease expertise, and serves as an advisor to many organizations and companies involved in the management of liver disease.

She has worked to expand access to liver disease care throughout the state of Arizona, running numerous outreach clinics in rural locations utilizing the ECHO telementoring program. She was awarded the American Academy of Nurse Practitioner State Award for Excellence in 2014 for her work with Hepatitis C patients in rural and underserved communities. Ann has also received several grants for expanding liver disease education programs and research grants for the study of hepatitis C and primary biliary cirrhosis.
